Bristol Myers Squibb Company $BMY Shares Bought by Intact Investment Management Inc.

Key Points

• Intact Investment Management raised its stake in Bristol Myers Squibb by 88.8% in Q4 to 106,100 shares worth $5.72 million, and institutional investors now own about 76.41% of the company.
• Bristol Myers Squibb beat Q1 estimates with $1.58 EPS vs. $1.42 expected and $11.49B revenue, and set FY2026 guidance of 6.050–6.350 EPS (analysts’ average ~6.29).
• The company pays a quarterly dividend of $0.63 ($2.52 annual), implying a 4.4% yield and a payout ratio of about 70.8%.

Intact Investment Management Inc. raised its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 88.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 106,100 shares of the biopharmaceutical company's stock after acquiring an additional 49,900 shares during the quarter. Intact Investment Management Inc.'s holdings in Bristol Myers Squibb were worth $5,723,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BMY. Novem Group raised its stake in Bristol Myers Squibb by 2.9% in the 4th quarter. Novem Group now owns 6,402 shares of the biopharmaceutical company's stock valued at $345,000 after purchasing an additional 183 shares during the last quarter. Dominguez Wealth Management Solutions Inc. raised its stake in Bristol Myers Squibb by 0.8% in the 4th quarter. Dominguez Wealth Management Solutions Inc. now owns 22,404 shares of the biopharmaceutical company's stock valued at $1,208,000 after purchasing an additional 185 shares during the last quarter. McLean Asset Management Corp raised its stake in Bristol Myers Squibb by 3.1% in the 4th quarter. McLean Asset Management Corp now owns 6,465 shares of the biopharmaceutical company's stock valued at $369,000 after purchasing an additional 192 shares during the last quarter. Bath Savings Trust Co raised its stake in Bristol Myers Squibb by 2.3% in the 4th quarter. Bath Savings Trust Co now owns 8,743 shares of the biopharmaceutical company's stock valued at $472,000 after purchasing an additional 198 shares during the last quarter. Finally, Traub Capital Management LLC raised its stake in Bristol Myers Squibb by 2.0% in the 4th quarter. Traub Capital Management LLC now owns 10,228 shares of the biopharmaceutical company's stock valued at $552,000 after purchasing an additional 200 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Stock Down 1.5%

BMY opened at $57.36 on Tuesday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The stock has a market capitalization of $117.11 billion, a price-to-earnings ratio of 16.11, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The business has a 50-day moving average of $59.56 and a two-hundred day moving average of $54.63. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion during the quarter, compared to analysts' expectations of $10.93 billion. During the same quarter in the previous year, the business earned $1.80 EPS. The firm's revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.29 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were issued a dividend of $0.63 per share. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. Bristol Myers Squibb's payout ratio is presently 70.79%.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the business's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.05% of the company's stock.

Analyst Upgrades and Downgrades

BMY has been the subject of several analyst reports. UBS Group reissued a "buy" rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Wells Fargo & Company restated an "outperform" rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Leerink Partners lifted their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an "outperform" rating in a report on Tuesday, January 13th. Scotiabank restated a "sector perform" rating and issued a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, Citigroup restated a "neutral" rating on shares of Bristol Myers Squibb in a report on Friday. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Hold" and a consensus target price of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.